These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer. Zhang S; Li W; Liang F Oncotarget; 2016 Jul; 7(30):48600-48606. PubMed ID: 27203206 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of Civelek AC; Niglio SA; Malayeri AA; Lin J; Gurram S; Chalfin HJ; Turkbey B; Valera V; Steinberg SM; Apolo AB Urol Oncol; 2021 Nov; 39(11):787.e17-787.e21. PubMed ID: 34140245 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138 [TBL] [Abstract][Full Text] [Related]
6. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129 [TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579 [TBL] [Abstract][Full Text] [Related]
8. Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer. Jiang J; Yang Z; Zhang Y; Xu X; Wang M; Hu S; Yao Z; Pan H; Zhang Y; Li D Clin Imaging; 2014; 38(6):797-801. PubMed ID: 24973077 [TBL] [Abstract][Full Text] [Related]
9. MRI fused with prone FDG PET/CT improves the primary tumour staging of patients with breast cancer. Garcia-Velloso MJ; Ribelles MJ; Rodriguez M; Fernandez-Montero A; Sancho L; Prieto E; Santisteban M; Rodriguez-Spiteri N; Idoate MA; Martinez-Regueira F; Elizalde A; Pina LJ Eur Radiol; 2017 Aug; 27(8):3190-3198. PubMed ID: 28004161 [TBL] [Abstract][Full Text] [Related]
10. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Gayed I; Vu T; Johnson M; Macapinlac H; Podoloff D Mol Imaging Biol; 2003; 5(1):26-31. PubMed ID: 14499159 [TBL] [Abstract][Full Text] [Related]
11. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796 [TBL] [Abstract][Full Text] [Related]
12. 2-Deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Iagaru A; Quon A; Johnson D; Gambhir SS; McDougall IR Mol Imaging Biol; 2007; 9(1):50-7. PubMed ID: 17051322 [TBL] [Abstract][Full Text] [Related]
13. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors]. Wu ZJ; Zhang YX; Wei H; Jia Q Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544 [TBL] [Abstract][Full Text] [Related]
15. Fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan contributes to the diagnosis and management of brucellar spondylodiskitis. Ioannou S; Chatziioannou S; Pneumaticos SG; Zormpala A; Sipsas NV BMC Infect Dis; 2013 Feb; 13():73. PubMed ID: 23388066 [TBL] [Abstract][Full Text] [Related]
16. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer? Schaefferkoetter JD; Carlson ER; Heidel RE J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746 [TBL] [Abstract][Full Text] [Related]
17. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer. Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451 [TBL] [Abstract][Full Text] [Related]
18. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
19. Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer. Yang Z; Pan L; Cheng J; Hu S; Xu J; Ye D; Zhang Y Int J Urol; 2012 Jul; 19(7):639-44. PubMed ID: 22452420 [TBL] [Abstract][Full Text] [Related]
20. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. Yen TC; Ng KK; Ma SY; Chou HH; Tsai CS; Hsueh S; Chang TC; Hong JH; See LC; Lin WJ; Chen JT; Huang KG; Lui KW; Lai CH J Clin Oncol; 2003 Oct; 21(19):3651-8. PubMed ID: 14512397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]